FDA "Least Burdensome" Draft Guidance Unhelpful, Medical Alley Says
This article was originally published in The Gray Sheet
FDA's recently released "least burdensome" draft guidance is not a useful tool for manufacturers seeking regulatory approvals, Medical Alley contends in comments submitted to the agency Nov. 23.
You may also be interested in...
FDA should consider postmarket controls for breakthrough devices as an alternative to randomized, controlled clinical studies as a "least burdensome" route to approval, a pan-industry task force suggests in Nov. 24 comments on FDA's draft guidance.
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.